Full Year 2014 – Conference Call Note

Dr. Rudolf Staudigl (CEO), Dr. Joachim Rauhut (CFO), March 17th, 2015
WACKER: Strong Volumes, Special Effects and Cost Reductions Define 2014 Performance

<table>
<thead>
<tr>
<th>in €m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% YoY</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>4,826.4</td>
<td>4,478.9</td>
<td>7.8</td>
<td>1,194.5</td>
<td>1,086.9</td>
<td>9.9</td>
</tr>
<tr>
<td>EBITDA</td>
<td>1,042.3*</td>
<td>678.7**</td>
<td>53.6</td>
<td>180.1</td>
<td>158.1</td>
<td>13.9</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>21.6%</td>
<td>15.2%</td>
<td>-</td>
<td>15.1%</td>
<td>14.5%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>443.3</td>
<td>114.3***</td>
<td>&gt;100</td>
<td>31.1</td>
<td>-5.5</td>
<td>n.a.</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>9.2%</td>
<td>2.6%</td>
<td>-</td>
<td>2.6%</td>
<td>-0.5%</td>
<td>-</td>
</tr>
<tr>
<td>Result for the period</td>
<td>195.4</td>
<td>6.3</td>
<td>&gt;100</td>
<td>-17.2</td>
<td>-19.3</td>
<td>-10.9</td>
</tr>
<tr>
<td>EPS in €</td>
<td>4.10</td>
<td>0.05</td>
<td>&gt;100</td>
<td>-0.32</td>
<td>-0.40</td>
<td>-20.0</td>
</tr>
</tbody>
</table>

*Includes specials in POLYSILICON: €206.3m
**Includes specials in POLYSILICON: €77.6m, SILICONES €13.7m
***Includes specials in Siltronic -€31.1m
2014 Group Sales Driven by Higher Demand in all Segments

Sales bridge in €m

Sales FY2014

FX-Effects

Pricing

Volume and Mix

Sales FY2013

4,000  4,500  5,000

Sales FY2013

Volume and Mix

Pricing

FX-Effects

Sales FY2014

327

39

327

-19

4,000  4,500  5,000
2015: Good Demand in Most Segments, Support from FX

WACKER

FY 2014 Comments

- Positive volume and product mix development
- Investment of €572m (2013: €504m) below depreciation of €599m (2013: €564m)
- Cost Reductions of about €200m, similar to previous year
- Net cash flow €216m
- Net debt increased to €1,081m (2013: €792m)
- Tax rate down to 46.5% (2013: 79.7%) driven by non tax deductible pre-operational costs and losses
- Net income improved significantly €195m (2013: €6m)

2015 Challenges and Opportunities

- Expect increasing volumes
- FY Sales expected to grow by a high single digit %, supported by FX
- Increase in EBITDA adjusted for special income (> €836m)
- Net cash flow positive, though substantially below last year
- Capex at around €700m as US capex gets more expensive (FX)
- Net debt to increase between €200m and €300m
- Depreciation below capex at around €625m
## Wacker Silicones: FY EBITDA Dampened by Price Pressure and General Cost Increases

<table>
<thead>
<tr>
<th>€m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% QoQ</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>1,733.6</td>
<td>1,672.2</td>
<td>3.7</td>
<td>419.6</td>
<td>403.5</td>
<td>4.0</td>
</tr>
<tr>
<td>EBITDA</td>
<td>209.8</td>
<td>230.2*</td>
<td>-8.9</td>
<td>33.8</td>
<td>51.0*</td>
<td>-33.7</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>12.1%</td>
<td>13.8%</td>
<td>-</td>
<td>8.1%</td>
<td>12.6%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>128.9</td>
<td>151.1</td>
<td>-14.7</td>
<td>13.0</td>
<td>31.0</td>
<td>-58.1</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>7.4%</td>
<td>9.0%</td>
<td>-</td>
<td>3.1%</td>
<td>7.7%</td>
<td>-</td>
</tr>
<tr>
<td>Capex</td>
<td>88.5</td>
<td>85.4</td>
<td>3.6</td>
<td>34.0</td>
<td>36.8</td>
<td>-7.6</td>
</tr>
</tbody>
</table>

*Includes positive special effects in Q4: Reversal of loss provision for siloxane €13.7m
Price Pressure, GDP Uncertainty and Plant Turnaround Held 2014 Back – Continue Focus on Shift to Specialties

WACKER SILICONES

FY 2014 Comments

- Good demand especially in electronic applications and automotive
- Higher volumes and improved product-mix
- Competitive intensity increases price pressure in all market segments
- Raw material prices stable yoy
- Utilization 95% (2013: 90%)
- EBITDA 2013 profited e.g. from reversal of loss provision for siloxane €13.7m and temporary labor cost reductions

2015 Challenges and Opportunities

- Volume growth at GDP, strong demand in emerging countries, softer in Europe
- Sales growth in all business sectors, especially in personal care, medical technology and electronics
- Continue growth of specialty shipments
- Silicon metal inflation increases raw material costs
- Expect to maintain high utilization
- EBITDA over FY 2014
- Capex at around €100m
SILICONES: Balancing Two Distinctive Performance Drivers

Specialties Volumes
(in siloxane equivalents (kt))

Siloxane Capacity Development
(Siloxane volume in kt)

- Interim target reached in 2014: 40% of 2012 siloxane base converted into specialties

*CAGR (12/17e): ~8%
*CAGR (12/17e): ~6%

* Plant turnaround in Nuenchritz in Q1 2014 restricted siloxane availability
## WACKER POLYMERS: Volume Increases Helped Fend off VAM Cost Inflation

<table>
<thead>
<tr>
<th>€m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% QoQ</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>1,064.4</td>
<td>978.7</td>
<td>8.8</td>
<td>252.2</td>
<td>213.2</td>
<td>18.3</td>
</tr>
<tr>
<td>EBITDA</td>
<td>149.5</td>
<td>147.8</td>
<td>1.2</td>
<td>23.6</td>
<td>22.6</td>
<td>4.4</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>14.0%</td>
<td>15.1%</td>
<td>-</td>
<td>9.4%</td>
<td>10.6%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>118.7</td>
<td>112.9</td>
<td>5.1</td>
<td>15.6</td>
<td>14.7</td>
<td>6.1</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>11.2%</td>
<td>11.5%</td>
<td>-</td>
<td>6.2%</td>
<td>6.9%</td>
<td>-</td>
</tr>
<tr>
<td>Capex</td>
<td>56.3</td>
<td>36.8</td>
<td>53.0</td>
<td>20.1</td>
<td>15.5</td>
<td>29.7</td>
</tr>
</tbody>
</table>
VAM Costs Expected to Decline in 2015 – EBITDA Upside

WACKER POLYMERS

FY 2014 Comments

- Increased volumes and slightly higher prices for dispersions and powder
- Strongest growth in Eastern Europe and India
- Raw material costs up: VAM* price increases and turnaround raised costs by about €30m in 2014
- Utilization 85% (2013: 82%)
- EBITDA only marginally higher

2015 Challenges and Opportunities

- Robust sales growth in both, dispersions and powder
- Growth driven by packaging applications and construction (increasing polymer modification of dry mortars)
- VAM* prices expected to decrease back to early 2014 levels
- Increase in FY EBITDA expected driven by volumes and FX tailwinds
- Capex at around €50m

*Vinyl Acetate Monomer
Capacity Expansion To Support Strong Global Demand

Burghausen/Germany
New dryer for powder business

Nanjing/China
New production plant for polyvinyl-acetate resins
WACKER BIOSOLUTIONS: Sales Increase Driven by Integration of Scil Proteins

<table>
<thead>
<tr>
<th>€m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% QoQ</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>176.2</td>
<td>158.4</td>
<td>11.2</td>
<td>43.7</td>
<td>39.3</td>
<td>11.2</td>
</tr>
<tr>
<td>EBITDA</td>
<td>23.6</td>
<td>23.6</td>
<td>0.0</td>
<td>4.6</td>
<td>5.5</td>
<td>-16.4</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>13.4%</td>
<td>14.9%</td>
<td>-</td>
<td>10.5%</td>
<td>14.0%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>13.6</td>
<td>17.2</td>
<td>-20.9</td>
<td>2.0</td>
<td>3.9</td>
<td>-48.7</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>7.7%</td>
<td>10.9%</td>
<td>-</td>
<td>4.6%</td>
<td>9.9%</td>
<td>-</td>
</tr>
<tr>
<td>Capex</td>
<td>8.4</td>
<td>10.2</td>
<td>-17.6</td>
<td>4.1</td>
<td>2.4</td>
<td>70.8</td>
</tr>
</tbody>
</table>
Asia Offers the Biggest Growth Opportunities

WACKER BIOSOLUTIONS

FY 2014 Comments

- Integration of ScilProteins for pharma proteins
- Good business development in food and pharma proteins
- Higher volumes and prices
- Markedly higher sales yoy
- EBITDA on a par with previous year

2015 Challenges and Opportunities

- New Gumbase capacity available in Nanjing
- Substantial sales growth following the complete integration of ScilProteins
- Growth driven by biologics and nutrition business
- Clear EBITDA increase
WACKER Biotech offers process development and GMP* manufacturing of Biologics in 2 state-of-the-art facilities

**Jena site**
- ~80 FTEs*
- 300L line
- EMA* filed
- FDA* meeting

**Halle site**
- ~80 FTEs*
- 1,500L line
- EMA* approved
- FDA* inspected

- Wacker Biotech offers cell line development, process development and cGMP* production to customers from pharmaceutical and biotech industries.
- Wacker Biotech focuses on technologies that enable production of novel protein classes and push productivity.

*GMP = Good Manufacturing Practice; EMA = European Medicines Agency, FDA = Food and Drug Administration; cGMP = current Good Manufacturing Practice; FTE = Full-time equivalent
WACKER POLYSILICON: FY EBITDA Margin without Special Effects at 31.5%

<table>
<thead>
<tr>
<th>€m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% QoQ</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>1,049.1</td>
<td>924.2</td>
<td>13.5</td>
<td>261.5</td>
<td>249.8</td>
<td>4.7</td>
</tr>
<tr>
<td>EBITDA</td>
<td>537.0*</td>
<td>233.9**</td>
<td>&gt;100</td>
<td>88.8</td>
<td>70.8</td>
<td>25.4</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>51.2%</td>
<td>25.3%</td>
<td>-</td>
<td>34.0%</td>
<td>28.3%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>305.3</td>
<td>0.1</td>
<td>&gt;100</td>
<td>31.4</td>
<td>12.6</td>
<td>&gt;100</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>29.1%</td>
<td>0.0%</td>
<td>-</td>
<td>12.0%</td>
<td>5.0%</td>
<td>-</td>
</tr>
<tr>
<td>Capex</td>
<td>334.5</td>
<td>290.0</td>
<td>15.3</td>
<td>132.3</td>
<td>63.9</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>

*Includes specials in POLYSILICON: €206.3m
**Includes specials in POLYSILICON: €77.6m
Strong Performance in 2014 – Solid Volumes, Improved Pricing and Special Effects

WACKER POLYSILICON

FY 2014 Comments

- WACKER FY 2014 shipments: 51kt (~4% growth yoy)
- MOFCOM and WACKER resolve AD discussion in Q1, WACKER exports into China without tariffs: price undertaking
- Sales rose substantially, supported by higher volumes and better prices
- Full utilization (2013: 90%)
- Special effects amount to €206.3m (2013: €77.6m)
- EBITDA more than doubled yoy (+41% excluding special effects)
- CapEx €335m (+15%), mostly for Tennessee

2015 Challenges and Opportunities

- As industry growth continues, volume and sales growth expected
- Demand for high quality polysilicon is solid
- TN ramp-costs budgeted at €80m
- Cost roadmap continues: Debottlenecking and TN expansion increase capacity to ~80kt by 2017
- EBITDA FY below 30% due to higher ramp cost
- FX may increase competiveness
Polysilicon Market: 11% Volume Growth Expected in 2015

Global Polysilicon Shipments (kt)

- Stable quarterly shipments throughout 2014
- Increasingly competitive C-Si PV drives polysilicon demand
- Silicon-based PV offers highest conversion efficiencies and proven long-term stability at lowest cost

Assumption: 2017: 80 GW (incl. 10% thin-film share); Silicon consumption < 5 g/Wp in 2017; Shipment figures incl. time-delay shipment/installation
Polysilicon Supply & Demand Broadly Balanced – High Quality Poly Supply Tightening

Global Polysilicon Demand (kt) versus Capacity of Active Manufacturers

- Reduced number of producers operating after consolidation phase in 2012 & 2013
- Additional capacity to come on stream in 2015
- Questionable whether new entrants are cost-effective

Sources: market surveys, industry announcements, WACKER estimate

PV market:
- 2013: 40 GW
- 2014: ~44-46 GW
- 2015: ~50-60 GW

Capacity Announcements
Active Capacities
Total Demand (HIGH CASE)
Total Demand (LOW CASE)
Electronic Demand
## Decreasing PV System Prices Open Up New Markets – USA and Asia with Highest Growth Potential

<table>
<thead>
<tr>
<th>Country</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014e</th>
<th>2015e</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>1.7</td>
<td>1.1</td>
<td>0.6</td>
<td>1.0 – 1.1</td>
<td>1.3 – 1.7</td>
</tr>
<tr>
<td>Germany</td>
<td>7.5</td>
<td>7.6</td>
<td>3.3</td>
<td>1.9</td>
<td>1.2 – 1.5</td>
</tr>
<tr>
<td>Italy</td>
<td>7.4</td>
<td>3.6</td>
<td>1.1</td>
<td>0.7 – 0.8</td>
<td>1.1 – 1.5</td>
</tr>
<tr>
<td>Europe other</td>
<td>3.3</td>
<td>4.9</td>
<td>5.8</td>
<td>5.2 – 5.8</td>
<td>5.0 – 6.6</td>
</tr>
<tr>
<td>Europe total</td>
<td>19.9</td>
<td>17.2</td>
<td>10.8</td>
<td>8.8 – 9.6</td>
<td>8.6 – 11.3</td>
</tr>
<tr>
<td>Australia</td>
<td>0.8</td>
<td>1.0</td>
<td>0.9</td>
<td>1.0 – 1.2</td>
<td>1.4 – 1.8</td>
</tr>
<tr>
<td>China</td>
<td>2.5</td>
<td>4.8</td>
<td>12.9</td>
<td>12.5 – 13.5</td>
<td>14.0 – 16.0</td>
</tr>
<tr>
<td>India</td>
<td>0.4</td>
<td>0.9</td>
<td>1.0</td>
<td>1.0</td>
<td>2.2 – 2.7</td>
</tr>
<tr>
<td>Japan</td>
<td>1.3</td>
<td>2.5</td>
<td>6.8</td>
<td>9.3</td>
<td>9.5 – 11.0</td>
</tr>
<tr>
<td>USA</td>
<td>1.9</td>
<td>3.3</td>
<td>4.8</td>
<td>6.2</td>
<td>8.0 – 9.2</td>
</tr>
<tr>
<td>Rest of World</td>
<td>1.3</td>
<td>2.1</td>
<td>2.8</td>
<td>5.0 – 5.7</td>
<td>6.0 – 8.1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>28 GW</td>
<td>32 GW</td>
<td>40 GW</td>
<td>~44 – 46 GW</td>
<td>~50 – 60 GW</td>
</tr>
</tbody>
</table>

Sources: EPIA 02/2012, 05/2013, 05/2014, Industry announcements, WACKER estimate
Construction at the Tennessee Polysilicon Site on Track

Progress in Tennessee

What to expect in 2015

- Ramp-up of production begins in H2
- Ramp of facility within 1 year, focus is on quality and cost
- Pre-operational and ramp-up costs budgeted at €80m in 2015
- Expect to produce first customer qualification material in 2015
Siltronic: Cost Reduction, Strong Volumes and First-Time Consolidation of Singapore 300 mm Shaped 2014

<table>
<thead>
<tr>
<th>€m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>% QoQ</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>% YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>853.4</td>
<td>743.0</td>
<td>14.9</td>
<td>223.2</td>
<td>174.6</td>
<td>27.8</td>
</tr>
<tr>
<td>EBITDA</td>
<td>114.0</td>
<td>26.5</td>
<td>&gt;100</td>
<td>37.7</td>
<td>11.5</td>
<td>&gt;100</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>13.4%</td>
<td>3.6%</td>
<td>-</td>
<td>16.9%</td>
<td>6.6%</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>-43.5</td>
<td>-95.9*</td>
<td>-54.6</td>
<td>0.0</td>
<td>-41.8*</td>
<td>-100.0</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>-5.1%</td>
<td>-12.9%</td>
<td>-</td>
<td>0.0%</td>
<td>-23.9%</td>
<td>-</td>
</tr>
<tr>
<td>Capex</td>
<td>40.7</td>
<td>30.9</td>
<td>31.7</td>
<td>19.2</td>
<td>11.7</td>
<td>64.1</td>
</tr>
</tbody>
</table>

*Includes special depreciation for disused assets of €31.1m
Siltronic: WACKER looks into Change in Ownership Structure

**Siltronic**

**FY 2014 Comments**

- Volume increase in all diameters, especially in 300mm
- Lower pricing and negative FX-effects
- Outstanding cost reduction track record
- Utilization 90% (2013: 77%)
- EBIT positive in Q4
- FY EBITDA improved, supported by the first-time consolidation of Siltronic Silicon Wafer

**2015 Challenges and Opportunities**

- Sales growth driven by slightly higher volumes and favorable FX
- 300mm expected to grow, 200mm to stay stable while SD decline slightly
- Operating at capacity limits
- Expect better FY EBITDA
- Depreciation declines in FY15 by about 20%
- Capex at around €90m
Siltronic: Track Record of Improved Productivity

300 mm Productivity in Germany
(Wafer shipped / hours paid (2009 set to 100))

- Close to 100% labor productivity improvement in 5 years in 300mm
- Singapore 300mm asset achieved similar improvement – Basis for further global optimization

Source: Company Information
Siltronic Group Stand-Alone Metrics: EBITDA-Level Maintained Despite Falling Prices

Adjusted Sales, EBITDA and Margin for Siltronic Group (in €m)

- Strong price decline in 2013 and 2014
- Volume growth in 2014
- Capex below depreciation since 2013
- Cash contribution 2013/2014 of €106m

Note: Adjusted EBITDA with full consolidation, adjusted for one-off items in excess of 5 million Euros
Wafer Industry Operates close to Capacity Limits as Demand Growth Continues – But Price Levels do not support Capex

Development of Wafer Diameters (mn cm² per month 3MMA*)

Source: SEMI up to Dec 2014; since Jul'12: data includes total GlobalWafers group

* 3MMA three month moving average
Wafer Market Returned to Growth in 2014 on the Back of Strong Demand in Key Semiconductor Applications

Silicon Wafer Demand (bn in²)

<table>
<thead>
<tr>
<th>Year</th>
<th>Demand</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>9.7</td>
</tr>
<tr>
<td>2011</td>
<td>9.4</td>
</tr>
<tr>
<td>2012</td>
<td>9.3</td>
</tr>
<tr>
<td>2013</td>
<td>9.3</td>
</tr>
<tr>
<td>2014</td>
<td>10.4</td>
</tr>
<tr>
<td>2015</td>
<td>10.7</td>
</tr>
<tr>
<td>2016</td>
<td>10.9</td>
</tr>
<tr>
<td>2017</td>
<td>11.4</td>
</tr>
<tr>
<td>2018</td>
<td>11.8</td>
</tr>
</tbody>
</table>

11% growth in 2014


Wafer Demand 2014 (bn in²) and Growth 2014/2015 (%)

- Mobility: 3.7bn in², ~15%
- Living: 1.9bn in², ~0%
- PC and Periphery: 1.8bn in², ~5%
- Industry: 1.0bn in², ~10%
- Automotive: 0.8bn in², ~10%
- Storage: 0.6bn in², ~15%
- Others: 0.2bn in², ~15%

Living and Industry expected to grow, Mobility the strongest growth driver.
POLYSILICON Strongest Contributor to EBITDA even without One Offs (40%)

**FY 2014 Sales**

- Siltronic: 21%
- WACKER BIOSOLUTIONS: 2%
- WACKER SILICONES: 36%
- WACKER POLYSILICON: 17%
- Others: 4%
- Total: €4,826.4m

**FY 2014 EBITDA**

- Siltronic: 1%
- WACKER BIOSOLUTIONS: 11%
- WACKER SILICONES: 52%
- WACKER POLYSILICON: 20%
- Others: 2%
- Total: €1,042.3m

1Based on external sales
Growth in all Regions: Asian Growth Dominates

FY 2014 Sales by Region, Changes YoY (%)

- Total: €4,826m
- 2,221; Asia & Others +11%
- 1,130; Europe w/o Germany +5%
- 811; Americas +7% +7% in USD\(^1\)
- 664; Germany +3%

\(^1\) Adjusted currency
## Balance Sheet (%)

<table>
<thead>
<tr>
<th>Category</th>
<th>Total</th>
<th>12/31/14</th>
<th>12/31/13</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td>€6.9bn</td>
<td>€6.3bn</td>
<td></td>
</tr>
<tr>
<td>Noncurrent Assets</td>
<td>70%</td>
<td>67%</td>
<td></td>
</tr>
<tr>
<td>Current Assets</td>
<td>23%</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>Securities, Cash &amp; Cash E.</td>
<td>7%</td>
<td>10%</td>
<td></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td>€6.9bn</td>
<td>€6.3bn</td>
<td></td>
</tr>
<tr>
<td>Equity</td>
<td>28%</td>
<td>35%</td>
<td></td>
</tr>
<tr>
<td>Pension Accruals</td>
<td>25%</td>
<td>17%</td>
<td></td>
</tr>
<tr>
<td>Prepayments</td>
<td>10%</td>
<td>13%</td>
<td></td>
</tr>
<tr>
<td>Financial Debt</td>
<td>23%</td>
<td>22%</td>
<td></td>
</tr>
<tr>
<td>Accruals &amp; Liabilities</td>
<td>14%</td>
<td>13%</td>
<td></td>
</tr>
</tbody>
</table>

### Characteristics 12/31/14
- Non current assets: €4,854m
- Securities, cash and cash equivalents: €521m
- Provisions for pensions: €1,758m
- Net financial debt: €1,081m
- Equity: €1,947m
- Prepayments received per 12/31/14: €689m
- CapEx: €572m (Q4: €229m)
Pension Deficit Grows: Low Interest Rates Trigger Substantial Increase in DBO

Pension Provisions (€m)

- DBO: Defined Benefit Obligation

Impact Pension Provisions on Equity (€m)

Other Equity Items / Changes not recognized in the income statement

*DBO: Defined Benefit Obligation
EBITDA Impacted by €206m Special Effects in 2014

<table>
<thead>
<tr>
<th>Special Effects (in €m)</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
</tr>
<tr>
<td>Silicones: Siloxane JV effects</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Polysilicon: Retained prepayments &amp; damages from cancelled contracts</td>
<td>32.2</td>
<td>23.8</td>
</tr>
<tr>
<td>EBITDA</td>
<td>32.2</td>
<td>23.8</td>
</tr>
<tr>
<td>Siltronic: Special depreciation for disused assets</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>32.2</td>
<td>23.8</td>
</tr>
</tbody>
</table>
Diverse Impacts from Raw Materials on WACKER in 2015

Impacts of decreasing Oil Price

- **POLYSILICON:**
  - Lower oil prices with no impact on PV installation programs
  - Minor benefit via gas costs for co-generation plants in Europe

- **POLYMERS:**
  - Substitution of naphtha based adhesives slows as competing systems benefit from lower inputs
  - Raw materials based on Ethylene expected to decline

- **SILICONES, BIOSOLUTIONS** and **Siltronic:**
  - No benefit from lower oil

Expected Price Development of Raw Materials

- **VAM**
  - Force Majeure situations resolved, price levels expected to return to pre-crisis level

- **Methanol**
  - Declines benefit **SILICONES**, but expected to be already embedded in pricing

- **Silicon Metal**
  - Industry consolidation in tariff protected markets
  - Production outages in Brazil
Raw Materials: Share of Top 4 Raw Materials Stable YoY

**Ethylene Contract (€/MT)**

- 02/13: 1,400
- 06/13: 1,300
- 10/13: 1,200
- 02/14: 1,100
- 06/14: 1,000
- 10/14: 900
- 02/15: 800

**Si-Metal Contract (€/MT)**

- 02/13: 2,300
- 06/13: 2,250
- 10/13: 2,200
- 02/14: 2,150
- 06/14: 2,100
- 10/14: 2,050
- 02/15: 2,000

**Raw Materials 2014 (€m)**

- Si Metal
- Ethylene
- Methanol
- VAM*
- Others

*VAM = Vinylacetate monomer

**Costs of top 4 raw materials 21% of chemicals segment sales**

Source: ICIS, Ethylene Market Price Europe, free delivered

Source: CRU-Provider, Si-Metal Contract Price Europe free delivered
1 Cent Change in USD/€ Exchange Rate had an Impact of €4.5m on FY-EBITDA in 2014, unhedged*

**USD/EURO Development**

**External Sales and Net USD Exposure**

- **Chemicals**: 3,029
- **Polysilicon**: 950
- **Siltronic**: 848

*Standard Hedging policy = 50% of net exposure, 12 months rolling forward using the average rate of the past 12 months*

**WACKER: Result FY 2014 versus Guidance**

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>Outlook 2014</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales (€m)</td>
<td>4,478.9</td>
<td>Mid-single-digit % increase</td>
<td>4,826.4 ✓</td>
</tr>
<tr>
<td>EBITDA (€m)</td>
<td>678.7</td>
<td>Approx. 1,000</td>
<td>1,042.3 ✓</td>
</tr>
<tr>
<td>EBITDA margin (%)</td>
<td>15.2</td>
<td>Substantial increase to over 20%</td>
<td>21.6 ✓</td>
</tr>
<tr>
<td>Group net income (€m)</td>
<td>6.3</td>
<td>Substantial improvement</td>
<td>195.4 ✓</td>
</tr>
<tr>
<td>Net cash flow (€m)</td>
<td>109.7</td>
<td>Markedly pos. NCF at prior-year level</td>
<td>215.7 ✓</td>
</tr>
<tr>
<td>CapEx (€m)</td>
<td>503.7</td>
<td>Approx. 550</td>
<td>572.2 ✓</td>
</tr>
<tr>
<td>Net financial debt (€m)</td>
<td>792.2</td>
<td>Increase of around 300</td>
<td>1,080.6 ✓</td>
</tr>
<tr>
<td>Depreciation (€m)</td>
<td>564.4</td>
<td>Approx. 600</td>
<td>599.0 ✓</td>
</tr>
<tr>
<td>ROCE (%)</td>
<td>2.2</td>
<td>Substantial increase</td>
<td>8.4 ✓</td>
</tr>
</tbody>
</table>
WACKER: First Guidance FY 2015 and beyond

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>Outlook 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales (€m)</td>
<td>4,826.4</td>
<td>High-single-digit % increase</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2016: Further increase)</td>
</tr>
<tr>
<td>EBITDA (€m)</td>
<td>1,042.3</td>
<td>Adjusted for special income; slight increase</td>
</tr>
<tr>
<td>EBITDA margin (%)</td>
<td>21.6</td>
<td>Substantially lower</td>
</tr>
<tr>
<td>Group net income (€m)</td>
<td>195.4</td>
<td>Below 2014</td>
</tr>
<tr>
<td>Net cash flow (€m)</td>
<td>215.7</td>
<td>Slightly positive, though substantially below 2014</td>
</tr>
<tr>
<td>CapEx (€m)</td>
<td>572.2</td>
<td>About 700</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2016: Decrease significantly)</td>
</tr>
<tr>
<td>Net financial debt (€m)</td>
<td>1,080.6</td>
<td>Increase between 200 and 300</td>
</tr>
<tr>
<td>Depreciation (€m)</td>
<td>599.0</td>
<td>Around 625</td>
</tr>
<tr>
<td>ROCE (%)</td>
<td>8.4</td>
<td>Lower</td>
</tr>
<tr>
<td>Tax Rate (%)</td>
<td>46.5</td>
<td>Slightly above 50</td>
</tr>
</tbody>
</table>
WACKER: Issuer, Contact and Additional Information

Issuer and Contact

- WACKER CHEMIE AG
  Hanns-Seidel-Platz 4
  D-81737 Munich

- Investor Relations contacts

  Mr. Joerg Hoffmann, CFA
  Tel. +49 89 6279 1633
  joerg.hoffmann@wacker.com

  Mrs. Judith Distelrath
  Tel. +49 89 6279 1560
  judith.distelrath@wacker.com

Additional Information

- ISIN: DE000WCH8881
- WKN: WCH888
- Deutsche Börse: WCH
- Ticker Bloomberg: CHM/WCH:GR
- Ticker Reuters: CHE/WCHG.DE
- Listing: Frankfurt Stock Exchange
  Prime Standard

Financial Calendar

- 04/30/15 – Q1 Results 2015
- 05/08/15 – Annual Shareholders’ Meeting
- 08/03/15 – Q2 Results 2015
- 10/29/15 – Q3 Results 2015
## WACKER: Sales in Chemicals on the level of previous Year

<table>
<thead>
<tr>
<th>Sales in €m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>%YoY</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>%YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICALS</td>
<td>2,974.2</td>
<td>2,809.3</td>
<td>5.9</td>
<td>715.5</td>
<td>656.0</td>
<td>9.1</td>
</tr>
<tr>
<td>WACKER SILICONES</td>
<td>1,733.6</td>
<td>1,672.2</td>
<td>3.7</td>
<td>419.6</td>
<td>403.5</td>
<td>4.0</td>
</tr>
<tr>
<td>WACKER POLYMERS</td>
<td>1,064.4</td>
<td>978.7</td>
<td>8.8</td>
<td>252.2</td>
<td>213.2</td>
<td>18.3</td>
</tr>
<tr>
<td>WACKER BIOSOLUTIONS</td>
<td>176.2</td>
<td>158.4</td>
<td>11.2</td>
<td>43.7</td>
<td>39.3</td>
<td>11.2</td>
</tr>
<tr>
<td>WACKER POLYSILICON</td>
<td>1,049.1</td>
<td>924.2</td>
<td>13.5</td>
<td>261.5</td>
<td>249.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Siltronic</td>
<td>853.4</td>
<td>743.0</td>
<td>14.9</td>
<td>223.2</td>
<td>174.6</td>
<td>27.8</td>
</tr>
<tr>
<td>Others</td>
<td>165.9</td>
<td>192.7</td>
<td>-13.9</td>
<td>46.2</td>
<td>51.6</td>
<td>-10.5</td>
</tr>
<tr>
<td>Consolidation</td>
<td>-216.2</td>
<td>-190.3</td>
<td>13.6</td>
<td>-51.9</td>
<td>-45.1</td>
<td>15.1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4,826.4</strong></td>
<td><strong>4,478.9</strong></td>
<td><strong>7.8</strong></td>
<td><strong>1,194.5</strong></td>
<td><strong>1,086.9</strong></td>
<td><strong>9.9</strong></td>
</tr>
</tbody>
</table>
## WACKER: EBITDA impacted through Price decrease in Siltronic and Polysilicon

<table>
<thead>
<tr>
<th>EBITDA in €m</th>
<th>FY 2014</th>
<th>FY 2013</th>
<th>%YoY</th>
<th>Q4 2014</th>
<th>Q4 2013</th>
<th>%YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICALS</td>
<td>382.9</td>
<td>401.6</td>
<td>-4.7</td>
<td>62.0</td>
<td>79.1</td>
<td>-21.6</td>
</tr>
<tr>
<td>WACKER SILICONES</td>
<td>209.8</td>
<td>230.2</td>
<td>-8.9</td>
<td>33.8</td>
<td>51.0</td>
<td>-33.7</td>
</tr>
<tr>
<td>WACKER POLYMERS</td>
<td>149.5</td>
<td>147.8</td>
<td>1.2</td>
<td>23.6</td>
<td>22.6</td>
<td>4.4</td>
</tr>
<tr>
<td>WACKER BIOSOLUTIONS</td>
<td>23.6</td>
<td>23.6</td>
<td>0.0</td>
<td>4.6</td>
<td>5.5</td>
<td>-16.4</td>
</tr>
<tr>
<td>WACKER POLYSILICON</td>
<td>537.0</td>
<td>233.9</td>
<td>&gt;100</td>
<td>88.8</td>
<td>70.8</td>
<td>25.4</td>
</tr>
<tr>
<td>Siltronic</td>
<td>114.0</td>
<td>26.5</td>
<td>&gt;100</td>
<td>37.7</td>
<td>11.5</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Others</td>
<td>12.7</td>
<td>14.7</td>
<td>-13.6</td>
<td>-4.7</td>
<td>-2.7</td>
<td>74.1</td>
</tr>
<tr>
<td>Consolidation</td>
<td>-4.3</td>
<td>2.0</td>
<td>n.a.</td>
<td>-3.7</td>
<td>-0.6</td>
<td>&gt;100</td>
</tr>
<tr>
<td></td>
<td><strong>1,042.3</strong></td>
<td><strong>678.7</strong></td>
<td><strong>53.6</strong></td>
<td><strong>180.1</strong></td>
<td><strong>158.1</strong></td>
<td><strong>13.9</strong></td>
</tr>
</tbody>
</table>